Obesity is a public health problem that has raised concerns worldwide and is often associated with hepatic steatosis. Hepassocin is a novel hepatokine that causes hepatic steatosis and induces insulin resistance (IR). However, the role of hepassocin in obesity remains obscure. Thus, the aim of this study was to investigate the relationship between hepassocin levels and obesity. In total, 371 subjects who had a normal weight (NW), were overweight, or were obese were enrolled. We found that hepassocin levels in subjects who were overweight (6,705 ± 1,707 pg/ml) or obese (7,335 ± 2,077 pg/ml) were significantly higher than those of subjects with a NW (5,767 ± 1,500 pg/ml) (p < .001, test for trend). A multiple linear regression analysis showed that the body‐mass index, waist circumference, nonalcoholic fatty liver disease, and homeostatic model assessment of IR were independently associated with hepassocin after adjusting for age, sex, high‐sensitivity C‐reactive protein, systolic blood pressure, high‐density lipoprotein‐cholesterol, log triglycerides, alanine transaminase, and the estimated glomerular filtration rate. This study provides evidence that subjects who were overweight or obese had significantly higher hepassocin levels than those with a NW. Hepassocin may be a useful biomarker in managing obesity and its related metabolic dysregulation.

中文翻译：

---

发现新型肝素，hepassocin在肥胖中的作用。

肥胖是一种公共卫生问题，已经引起全世界的关注，并且通常与肝脂肪变性相关。Hepassocin是一种新型肝因子，可引起肝脂肪变性并诱导胰岛素抵抗（IR）。但是，hepassocin在肥胖中的作用仍然不清楚。因此，本研究的目的是研究肝素球菌素水平与肥胖之间的关系。共有371名体重正常（NW），超重或肥胖的受试者入选。我们发现超重（6,705±1,707 pg / ml）或肥胖（7,335±2,077 pg / ml）受试者的Hepassocin水平明显高于NW（5,767±1,500 pg / ml）（p <.001，测试趋势）。多元线性回归分析显示，在调整了年龄，性别，高敏C反应蛋白，收缩压后，体重指数，腰围，非酒精性脂肪肝疾病和IR的稳态模型评估与Hepassocin独立相关。 ，高密度脂蛋白胆固醇，对数甘油三酸酯，丙氨酸转氨酶和估计的肾小球滤过率。这项研究提供的证据表明，超重或肥胖的受试者的肝素水平明显高于西北部的受试者。Hepassocin可能是控制肥胖症及其相关代谢异常的有用生物标志物。